〔Abstract〕 Objective To investigate the relationship between DNA damage repair gene XPG rs873601 polymorphism and the efficacy and prognosis of chemotherapy for lung cancer platinum drugs, so as to provide a scientific theoretical basis for accurate treatment of lung cancer patients. Methods 120 patients with lung cancer who received platinum-based chemotherapy were confirmed by pathology. After informed consent was obtained, we extracted peripheral blood DNA from 2-3 ml of peripheral venous bloodand detected the polymorphism of XPG rs873601 locus by mass spectrometry. WHO′s solid tumor efficacy evaluation criteria were used to determine the efficacy of chemotherapy for patients, and the survival of patients was obtained by telephone follow-up and other methods. Results Among 120 patients with lung cancer, the frequency distribution of the three genotypes of the XPSrs873601 was 53(44.2%), 61(50.8%), and 6(5%), which complied with the Hardy-Weinberg law of genetic balance(χ2=4.81).The total effective rate of chemotherapy was 32.5%. Patients with the XPG gene rs873601 AA genotype had the highest effective rate of chemotherapy, reaching 43.4%, while the GG genotype had the lowest, only 16.7%. The difference in efficacy between different genotypes was statistically significant(χ2=7.747,P=0.046). The total one-year survival rate of 120 lung cancer patients was 73.2%, the five-years survival rate was 20.8%, and the XPG gene rs873601 AA genotype had the lowest survival rate, the one-year survival rate was 60.4%, the five-years survival rate was 18.3%, and there was no statistically significant difference in survival rates between SNP(χ2=3.300,P=0.348). Conclusion XPG rs873601 polymorphism is associated with the efficacy of platinum-based chemotherapy for lung cancer, and it can be used as one of the markers for predicting the effectiveness of chemotherapy for lung cancer.